Human papillomavirus vaccine, L1 type 16, 18: all 55 studies that test it

Page 1 of 1. Open to participants first (1), then studies with results posted, then the rest; newest registration first within each.

• Candida Antigen and Bivalent HPV Vaccine in the Treatment of Multiple WartsRecruitingNCT05291845Phase 2
• Single Dose of Cervarix Vaccine in Girls or Three Doses of Gardasil Vaccine in Women for the Prevention of Human Papillomavirus Infection, the PRIMAVERA-ESCUDDO TrialCompletedNCT03728881Phase 3Results posted
• Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Cervarix®CompletedNCT02979535Phase 3Results posted
• Safety and Immunogenicity of GSK Biologicals' HPV-16/18 L1 VLP AS04 Vaccine (GSK-580299) in Healthy Female Children 4-6 Years OldCompletedNCT01627561Phase 3Results posted
• Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' Human Papillomavirus (HPV) Vaccine (GSK-580299) and Merck's Gardasil Vaccine When Administered According to Alternative 2-dose Schedules in 9-14 Year Old FemalesCompletedNCT01462357Phase 3Results posted
• Safety Evaluation of a Human Papillomavirus (HPV) Vaccine in Healthy Female Control Subjects From the GSK HPV 023 StudyCompletedNCT01418937Phase 3Results posted
• Evaluation of Immunogenicity and Safety of Two 2-dose Human Papillomavirus (HPV) Vaccine Schedules in 9-14 Year Old GirlsCompletedNCT01381575Phase 3Results posted
• Study to Assess Immune Responses and Safety of the GSK-580299 Vaccine in Healthy Women (26 to 45 Years)CompletedNCT01277042Phase 3Results posted
• The Safety Evaluation of the GSK-580299 Vaccine in Women From the Control Group in the Primary NCT00294047 StudyCompletedNCT01249365Phase 3Results posted
• Safety Evaluation of the GSK-580299 Vaccine in Women From the Control Group in the Primary NCT00294047 StudyCompletedNCT01190189Phase 3Results posted
• Gynaecological Follow-up of a Subset of HPV-015 (NCT00294047) Study SubjectsCompletedNCT01190176Phase 3Results posted
• Evaluation of Safety and Immunogenicity of a Human Papillomavirus (HPV) Vaccine in Human Immunodeficiency Virus (HIV) Infected FemalesCompletedNCT01031069Phase 4Results posted
• Immunogenicity and Safety Study of GSK Biologicals' Human Papillomavirus 580299 Vaccine in Healthy Female SubjectsCompletedNCT00996125Phase 3Results posted
• Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Brazil, Taiwan or ThailandCompletedNCT00849381Phase 3Results posted
• Safety Study of GSK Biologicals' HPV Vaccine (GSK-580299) in Healthy Female Subjects.CompletedNCT00811798Phase 3Results posted
• Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the USCompletedNCT00799825Phase 3Results posted
• A Study to Assess the Safety and Reactogenicity of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) Vaccine (Cervarix) in Healthy Female Filipino Subjects Vaccinated According to the Prescribing Information From the Age of 10 Years Onwards.TerminatedNCT00730847Phase 4Results posted
• Evaluation of Immunogenicity and Safety of Human Papillomavirus (HPV) Vaccine Co-administered With Another Vaccine in Healthy Female SubjectsCompletedNCT00652938Phase 3Results posted
• Immunogenicity and Safety of a Commercially Available Vaccine Co-administered With GSK HPV Vaccine (580299)CompletedNCT00637195Phase 3Results posted
• Safety and Immunogenicity of GlaxoSmithKline Biologicals' HPV Vaccine 580299 (Cervarix) in HIV Infected FemalesCompletedNCT00586339Phase 2Results posted
• Evaluation of Safety and Immunogenicity of Co-administering Human Papillomavirus Vaccine With Another Vaccine in Healthy Female SubjectsCompletedNCT00578227Phase 3Results posted
• A Single Centre Study to Evaluate the Safety and Immunogenicity of the Human Papillomavirus Vaccine (GSK-580299) in Chinese FemalesCompletedNCT00549900Phase 1Results posted
• Follow-up Study to Evaluate the Safety and Immunogenicity of a HPV Vaccine (580299) in North AmericaCompletedNCT00546078Phase 2Results posted
• Partially Blind Study to Evaluate Immunogenicity & Safety of GSK Bio's HPV Vaccine 580299 in Healthy Women Aged 9-25 YrsCompletedNCT00541970Phase 1Results posted
• Effectiveness, Safety and Immunogenicity of GSK Biologicals' HPV Vaccine GSK580299 (Cervarix) Administered in Healthy AdolescentsCompletedNCT00534638Phase 4Results posted
• Follow-up Study to Evaluate the Long-term Efficacy of the HPV Vaccine (580299) in Healthy Young Adult Women in BrazilCompletedNCT00518336Phase 2Results posted
• Immunogenicity and Safety of GSK Biologicals' HPV Vaccine 580299 in Healthy Japanese Females 10-15 Years of AgeCompletedNCT00492544Phase 3Results posted
• A Study to Evaluate the Immune Response and Safety of GSK Biologicals' HPV-16/18 L1 VLP AS04 Vaccine/Cervarix TM Vaccine in Healthy Females Aged 15-25 YearsCompletedNCT00485732Phase 3Results posted
• Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) Vaccine (GSK580299) in Healthy Female Subjects 10-25 Years of Age.CompletedNCT00481767Phase 3Results posted
• Complementary Testing to Evaluate Immunogenicity of Human Papillomavirus (HPV) Vaccine (580299) in Healthy Female Subjects Aged >/= 26 YearsCompletedNCT00456807Phase 3Results posted
• Immunogenicity of GlaxoSmithKline Biological's Human Papillomavirus (HPV) Vaccine (580299) Versus Merck's Gardasil® in Healthy Females 18-45 Years of AgeCompletedNCT00423046Phase 3Results posted
• Study to Evaluate the Immune Response and Safety of GSK Biologicals' HPV Vaccine in Healthy Women Aged 18-35 YearsCompletedNCT00345878Phase 3Results posted
• Evaluation of the Immune and Safety Response of GlaxoSmithKline (GSK) Biologicals' HPV Vaccine in Healthy Indian WomenCompletedNCT00344032Phase 3Results posted
• Human Papillomavirus (HPV) Vaccine Consistency and Non-inferiority Trial in Young Adult WomenCompletedNCT00337818Phase 3Results posted
• Human Papilloma Virus (HPV) Vaccine Trial in Young Adolescent Women With GlaxoSmithKline Biologicals' (GSK Bio) HPV-16/18 VaccineCompletedNCT00316706Phase 3Results posted
• Human Papillomavirus (HPV) Vaccine (Cervarix TM) Efficacy, Immunogenicity & Safety Trial in Adult Japanese Women With GSK Biologicals HPV-16/18 VaccineCompletedNCT00316693Phase 2Results posted
• Study to Evaluate the Efficacy of the Human Papillomavirus Vaccine in Healthy Adult Women of 26 Years of Age and OlderCompletedNCT00294047Phase 3Results posted
• Evaluation of the Immune Responses of GSK Biologicals' HPV Vaccine Following Manufacturing Process Adaptation.CompletedNCT00250276Phase 3Results posted
• Human Papilloma Virus (HPV) Vaccine Immunogenicity and Safety Trial in Young and Adult Women With GSK Biologicals' HPV-16/18CompletedNCT00196937Phase 3Results posted
• Vaccine To Prevent Cervical Intraepithelial Neoplasia or Cervical Cancer in Younger Healthy ParticipantsCompletedNCT00128661Phase 3Results posted
• Human Papilloma Virus (HPV) Vaccine Efficacy Trial Against Cervical Pre-cancer in Young Adults With GlaxoSmithKline (GSK) Biologicals HPV-16/18CompletedNCT00122681Phase 3Results posted
• Immunogenicity and Safety of Sequential 2vHPV-9vHPV Vaccination in Girls Aged 9-14 YearsActive, not recruitingNCT07281677Phase 4
• Single-Dose HPV Vaccination for the Prevention of Cervical Cancer in Young Adult Women in Costa Rica, The PRISMA ESCUDDO TrialActive, not recruitingNCT05237947Phase 4
• Lot Consistency Clinical Trial of Bivalent HPV Vaccine in 9 to 30 Years Old Healthy FemalesCompletedNCT04965350Phase 3
• Safety and Effects of Using Prime-boost HIVIS DNA and MVA-CMDR Vaccine Regimens With or Without Toll-like Receptor 4 Agonist on HIV Reservoirs in Perinatally HIV Infected Children and YouthCompletedNCT04301154Phase 1
• Comparing One or Two Doses of the Human Papillomavirus Vaccine for the Prevention of Human Papillomavirus Infection, ESCUDDO StudyActive, not recruitingNCT03180034Phase 4
• FASTER-Tlalpan Study in Mexico: HPV Vaccination Impact on Cervical Cancer Screening ProgramCompletedNCT03105856Phase 4
• Comparing Health Services Interventions for the Prevention of HPV-related CancerCompletedNCT02837926Phase 4
• A Dose Reduction Immunobridging and Safety Study of Two HPV Vaccines in Tanzanian GirlsActive, not recruitingNCT02834637Phase 3
• Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus Vaccine (Cervarix™) When Co-administered With GSK Biologicals' Hepatitis A Vaccine (Havrix®) in Healthy Female Adolescents Aged 9-14 YearsWithdrawnNCT02082639Phase 3
• Study of the Molecular Mechanisms Underlying the Cross-neutralizing Capacity of AS04-adjuvanted HPV Vaccine (Cervarix®) in Comparison With the Aluminiumhydroxyphosphate Sulphate Adjuvanted HPV Vaccine (Gardasil®)CompletedNCT01914367Phase 4
• Immune Response to Bivalent and Tetravalent Human Papillomavirus Vaccine in HIV Infected AdultsCompletedNCT01386164Phase 4
• Efficacy and Immunomodulation Study of Simultaneous Human Papillomavirus/ Hepatitis B (HPV/HBV) VaccinationTerminatedNCT01082861Phase 4
• Reactogenicity Study of Cervarix and Gardasil in UK Adolescent GirlsCompletedNCT00956553Phase 4
• Efficacy Study of HPV-16/18 Vaccine (GSK 580299) to Prevent HPV-16 and/or -18 Cervical Infection in Young Healthy WomenCompletedNCT00689741Phase 2

← Human papillomavirus vaccine, L1 type 16, 18 overview